anti-IgE antibody — Interim data
Q3 2026
"We look forward to our upcoming clinical milestones, including data from Ascendant Health's ongoing Phase 2 CSU study in China, which is expected by the end of the third quarter of 2026."Source filing
CUE biotech catalysts & pipeline
CUE BIOPHARMA INC · Data as of 2026-09-08
Upcoming catalysts
CUE-221 — Topline data
Q3 2026
Phase 2 data readout in Chronic Spontaneous Urticaria anticipated by the end of the third quarter of 2026Source filing
CUE-401 — Initial data
H2 2026
We anticipate receiving human safety data in the second half of 2026 and human proof-of-concept data in the second half of 2027.Source filing
CUE-401 — IND submission
Late 2026
Company anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026Source filing
CUE-100 series — IND submission
2027
Compelling data generated in preclinical models of multiple solid tumors, including pancreatic and ovarian, demonstrates the clinical potential of this novel immunotherapy approach with IND enabling studies on track for 2027 submissionSource filing
CUE-401 — Initial data
H2 2027
We anticipate receiving human safety data in the second half of 2026 and human proof-of-concept data in the second half of 2027.Source filing